Tuesday, October 16, 2018
Investigator(s): Ashraf S Ibrahim, PhD

Mucormycosis is a drug-resistant fungal infection that attacks patients with weakened immune systems and those who have suffered significant trauma. The infection can be easily missed by physicians because it is so rare and reliable diagnostic assay is lacking. Even when correctly diagnosed, it is often far too late and after the infection has spreads rapidly to vital organs, making most therapies ineffective. The mortality rate for those infected with mucormycosis is around 50%, according to the U.S. centers for Disease Control and Prevention.

Thursday, September 20, 2018

LA BioMed President and Chief Executive Officer David Meyer, Ph.D., is set to elaborate on the future of the local bioscience industry during a panel discussion later today at the Los Angeles County 2018 Bioscience Summit.  Meyer will also moderate a panel discussion about incubation and capital for start-ups.

Friday, September 14, 2018

LA BioMed, an independent biomedical research organization, hosted its fifth annual Innovation Showcase on September 13th in Manhattan Beach. The event featured some of biotechnology’s most promising start-ups and spotlighted 32 promising new bioscience companies.  

Monday, September 10, 2018

LA BioMed invites media to their fifth annual Innovation Showcase on September 13th at westdrift in Manhattan Beach, CA. The Showcase will highlight some of biotechnology’s most promising start-ups and venture capital leaders.

Biotech start-up entrants from the growing incubation hub of LA will showcase innovation in next generation medical therapies, devices and diagnostics from some of the worlds’ leading scientists. Highlights from the 32 featured companies include:

Wednesday, September 5, 2018

LA BioMed, an independent biomedical research organization, announced it will host its fifth annual Innovation Showcase on September 13th at westdrift Manhattan Beach.  The Showcase highlights biotechnology’s most promising start-ups and venture capital leaders.

Wednesday, August 29, 2018
New research building render

LA BioMed announced that it has closed on the sale of its $49,835,000 Series 2018 Tax-Exempt Revenue Bonds issued by the California Health Facilities Financing Authority (CHFFA).  The proceeds of the revenue bond sale, which was led by Wells Fargo Securities, will be used to finance various capital improvements on the LA BioMed campus, including constructing and equipping a new biomedical res

Thursday, August 9, 2018

Acinetobacter bacteriaA groundbreaking study by LA BioMed researchers shows promising results for a potential vaccine for deadly drug-resistant bacteria also known as superbugs.   

Thursday, August 2, 2018

LA BioMed announced the launch of two new male contraceptive studies. The preliminary study of the pill showed that the oral contraceptive appears to be safe and effective when taken daily. Current methods of male contraception include vasectomy, condoms, withdrawal, and fertility awareness.

 

Thursday, July 26, 2018

LA BioMed spinoff, Emmaus Life Sciences has announced that The New England Journal of Medicine has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.